Cue Biopharma, Inc. (CUE)

In April 2025, Cue Biopharma entered into a strategic collaboration with Boehringer Ingelheim for CUE-501, raised approximately $20 million through a public offering, and regained worldwide rights for CUE-401. In May 2025, the company reported its first-quarter financial results. In June 2025, the CFO departed, and the company received positive FDA feedback on CUE-401. In August 2025, Cue Biopharma reported its second-quarter financial results, exceeding EPS estimates, and announced new complete response and a confirmed 50% overall response rate in a trial of CUE-101. In November 2025, Cue Biopharma entered a strategic collaboration with ImmunoScape, announced the departure of its Chief Medical Officer, reported its third-quarter financial results, and appointed a new President and CEO. As of November 2025, the stock price has decreased by 42.6% year-to-date and 18.77% in the past month.

Cue Biopharma is a clinical-stage biopharmaceutical company focused on developing novel biologics for cancer and autoimmune disorders, its products are not yet commercialized and therefore do not exhibit traditional demand seasonality in the market. The diseases Cue Biopharma targets typically do not have seasonal fluctuations in incidence or treatment demand. The company's current focus is on advancing its pipeline through clinical trials and securing partnerships, rather than managing commercial product demand.

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing injectable biologic drugs for modulating the human immune system to treat cancers and autoimmune disorders. The company's Immuno-STAT™ platform is designed to selectively engage and modulate disease-specific T cells. Its major pipeline products include CUE-101, in Phase 1b clinical trials for HPV+ recurrent metastatic head and neck squamous cell carcinoma; CUE-102, in Phase 1b clinical trials for late-line recurrent metastatic WT1+ cancers; CUE-103; CUE-401, in preclinical trials for autoimmune diseases; and CUE-501, a treatment for autoimmune disease via anti-viral T cell-mediated depletion of B cells.

Cue Biopharma, Inc. is headquartered in Boston, Massachusetts, United States. Its research and manufacturing activities are primarily conducted within the United States. The company's strategic collaborations and license agreements extend its reach internationally, including partnerships with LG Chem, Ltd., Ono Pharmaceutical Co., Ltd, and Boehringer Ingelheim International GmbH.

As of July 2025, Cue Biopharma has an ESG "Severe Risk" rating. Recent events have the potential to positively influence its reputation. The ImmunoScape licensing agreement provides near-term cash flow and positions Cue Biopharma at the forefront of collaborative oncology innovation. The CUE-401 development program received validation following the 2025 Nobel Prize in Physiology or Medicine recognizing related scientific breakthroughs in immune regulation, aligning with Cue Biopharma's approach to treating autoimmune diseases.

Cue Biopharma has 64 institutional owners and shareholders, holding a total of 18,753,420 shares. Major institutional owners include Bleichroeder LP, Catalytic Wealth RIA, LLC, Vanguard Group Inc., VEXMX - Vanguard Extended Market Index Fund Investor Shares, VTSMX - Vanguard Total Stock Market Index Fund Investor Shares, Geode Capital Management, Llc, Boothbay Fund Management, Llc, Robertson Stephens Wealth Management, LLC, BlackRock, Inc., and FSMAX - Fidelity Extended Market Index Fund. Individual insiders own approximately 0.337% of the company's shares.